Literature DB >> 22493359

Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.

Aikaterini Stoyianni1, Anna Goussia, George Pentheroudakis, Vassiliki Siozopoulou, Elli Ioachim, Dimitrios Krikelis, Vassilios Golfinopoulos, Andres Cervantes, Mattheos Bobos, Theodoros Fotsis, Sofia Bellou, Georgios Fountzilas, Vassiliki Malamou-Mitsi, Nicholas Pavlidis.   

Abstract

BACKGROUND: The epithelial to mesenchymal transition (EMT) has been associated with metastatic dissemination and poor outcome in several solid tumour types. Our aim was to study its incidence and its prognostic significance in cancer of unknown primary (CUP). PATIENTS AND METHODS: One hundred tumour samples of CUP were loaded in tissue microarrays and were studied for immunohistochemical (IHC) expression of E-cadherin, N-cadherin, vimentin, the EMT transcription factor (SNAIL) and the stem cell marker octamer-binding transcription marker 4(OCT4). An EMT phenotype was defined as low expression of E-cadherin, expression of N-cadherin with/without vimentin with concomitant expression of SNAIL, as assessed by percentage of tumour cell staining.
RESULTS: Among 100 CUP cases, the histological diagnosis was adenocarcinoma in 55, squamous carcinoma in 20 and undifferentiated carcinoma in 15, with a high grade seen in 46. Therapy consisted of palliative chemotherapy, mostly platinum based. The median progression-free survival and overall survival (OS) were 7 and 12 months respectively. Distributional studies resulted in selection of IHC cut-offs for E-cadherin (negative when expressed in <60% of tumour cells), N-cadherin, vimentin (positive when expressed in ≥40% of tumour cells), SNAIL (positive when stained in ≥80% of tumour cells). An EMT phenotype was observed in 8 cases (8.1%) and was strongly associated with poor OS (median OS EMT(-)=13 months vs. median OS EMT(+)=8 months, p=0.023). When we used staining intensity (H-Score), an EMT phenotype was observed in 16 patients and carried borderline adverse prognostic utility for outcome (median OS 9 vs. 14 months, p=0.07). The presence of the EMT phenotype correlated significantly with male gender, high grade and presence of visceral metastases (χ(2) p<0.05), while EMT mediator expression was correlated to high NOTCH 2/3 expression. Other factors, prognostic for poor survival, were male gender, PS≥2, non-platinum therapy (χ(2) p<0.05).
CONCLUSION: EMT is infrequently seen in tumours of CUP. However, an adverse prognostic significance for patient outcome has been identified and may warrant studies of therapeutic targeting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493359

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

Review 1.  Progress in refining the clinical management of cancer of unknown primary in the molecular era.

Authors:  Elie Rassy; Nicholas Pavlidis
Journal:  Nat Rev Clin Oncol       Date:  2020-04-29       Impact factor: 66.675

2.  Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.

Authors:  Dimitrios Krikelis; George Pentheroudakis; Anna Goussia; Vassiliki Siozopoulou; Mattheos Bobos; Dimitrios Petrakis; Aikaterini Stoyianni; Vassilios Golfinopoulos; Andres Cervantes; Tudor Ciuleanu; George Fountzilas; Vassiliki Malamou-Mitsi; Nicholas Pavlidis
Journal:  Clin Exp Metastasis       Date:  2012-04-19       Impact factor: 5.150

3.  Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study.

Authors:  A Stoyianni; G Pentheroudakis; H Benjamin; A Cervantes; K Ashkenazi; G Lazaridis; N Pavlidis; Y Spector
Journal:  Clin Transl Oncol       Date:  2013-11-27       Impact factor: 3.405

Review 4.  The Notch signaling pathway as a mediator of tumor survival.

Authors:  Kathleen M Capaccione; Sharon R Pine
Journal:  Carcinogenesis       Date:  2013-04-12       Impact factor: 4.944

5.  Strong correlation between N-cadherin and CD133 in breast cancer: role of both markers in metastatic events.

Authors:  Carolin Bock; Christina Kuhn; Nina Ditsch; Regina Krebold; Sabine Heublein; Doris Mayr; Sophie Doisneau-Sixou; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-25       Impact factor: 4.553

6.  Tumor-infiltrating immune cells: triggers for tumor capsule disruption and tumor progression?

Authors:  Bin Jiang; Jeffrey Mason; Anahid Jewett; Min-ling Liu; Wen Chen; Jun Qian; Yijiang Ding; Shuqing Ding; Min Ni; Xichen Zhang; Yan-gao Man
Journal:  Int J Med Sci       Date:  2013-03-05       Impact factor: 3.738

7.  HMGA2 is associated with epithelial-mesenchymal transition and can predict poor prognosis in nasopharyngeal carcinoma.

Authors:  You-You Xia; Li Yin; Hao Tian; Wen-Jie Guo; Ning Jiang; Xue-Song Jiang; Jing Wu; Meng Chen; Jian-Zhong Wu; Xia He
Journal:  Onco Targets Ther       Date:  2015-01-17       Impact factor: 4.147

8.  The Synthetic β-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways.

Authors:  Wen-Chin Chiu; Yi-Chen Lee; Yu-Han Su; Yen-Yun Wang; Chun-Hao Tsai; Yi-An Hou; Chie-Hong Wang; Ying-Fong Huang; Chih-Jen Huang; Shah-Hwa Chou; Pei-Wen Hsieh; Shyng-Shiou F Yuan
Journal:  PLoS One       Date:  2016-11-22       Impact factor: 3.240

Review 9.  A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists.

Authors:  Nicholas Pavlidis; Hussein Khaled; Rabab Gaafar
Journal:  J Adv Res       Date:  2014-11-21       Impact factor: 10.479

10.  The role of microRNA-200 in progression of human colorectal and breast cancer.

Authors:  Linda Bojmar; Elin Karlsson; Sander Ellegård; Hans Olsson; Bergthor Björnsson; Olof Hallböök; Marie Larsson; Olle Stål; Per Sandström
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.